Article
[Effectiveness of gefitinib (Iressa) as first-line therapy for inoperable non-small-cell lung cancer with mutated EGFR gene (phase II study)].
Voprosy onkologii - 1 Jan 2010
Moiseenko V M, Protsenko S A, Semenov I I, Moiseenko F V, Levchenko E V, Barchuk A S, Matsko D E, Ivantsov A O, Ievleva A G, Mitiushkina N V, Togo A V, Imianitov E N
Abstract excerpt
Tumor regression was reported in 20-30% of patients with inoperable non-small-cell lung cancer (NSLC) following standard first-line chemotherapy. Clinical trials with second-line gefitinib (Iressa) showed a strikingly high response in patients with mutated EGFR. However, clinical experience with gefitinib as first-line therapy had been limited to small-scale trials mostly among subjects of Asian origin. Our study...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.